Valuation

MAZEMaze Therapeutics Inc.

StockNasdaqUnited StatesHealth careEU retail: available

+0.1% today · −1.2% over a year

2/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 12% of the instruments we score

Priced higher than most peers. No dividend.

Maze Therapeutics Inc. (MAZE) valuation against sector peers: P/B 3.9, free-cash-flow yield −6.1%.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricMAZESector medianvs median
P/E—30.6 · n=152—
P/B3.94.0 · n=305near the median
P/S—4.4 · n=297—
EV/EBIT—25.8 · n=139—
Free-cash-flow yield−6.1%1.4% · n=287527% below
Dividend yield0.00%0.00% · n=358—
Return on equity−37.3%−3.7% · n=306—
Return on invested capital−50.3%0.4% · n=27511,631% below
Gross margin—61.7% · n=202—
Net debt / EBITDA—1.31 · n=146—

Value factor: 21 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co45.435.8—1.5%0.6%7/10
JNJJohnson & Johnson40.58.0—3.2%1.9%8/10
ABBVAbbVie80.6—33.83.6%3.0%5/10
UNHUnitedHealth25.93.519.16.5%2.2%9/10
MRKMerck109.68.3—4.6%2.4%9/10
TMOThermo Fisher Scientific37.44.936.72.8%0.3%10/10
AMGNAmgen27.920.925.24.2%2.2%7/10
GILDGILEAD—16.7—6.6%2.0%5/10
ABTAbbott28.43.426.84.1%3.0%6/10
PFEPfizer38.72.0—6.5%7.3%1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Jun 2026 · filed 11 Aug 2026